BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pahlavanneshan S, Sayadmanesh A, Ebrahimiyan H, Basiri M. Toll-Like Receptor-Based Strategies for Cancer Immunotherapy. J Immunol Res 2021;2021:9912188. [PMID: 34124272 DOI: 10.1155/2021/9912188] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
Number Citing Articles
1 Zhang B, Chen X, Tang G, Zhang R, Li J, Sun G, Yan X, Fan K. Constructing a nanocage-based universal carrier for delivering TLR-activating nucleic acids to enhance antitumor immunotherapy. Nano Today 2022;46:101564. [DOI: 10.1016/j.nantod.2022.101564] [Reference Citation Analysis]
2 Pan W, Song K, Zhang Y, Yang C, Zhang Y, Ji F, Zhang J, Shi J, Wang K. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs. Front Immunol 2022;13:982486. [DOI: 10.3389/fimmu.2022.982486] [Reference Citation Analysis]
3 Lee WS, Kim DS, Kim JH, Heo Y, Yang H, Go EJ, Kim JH, Lee SJ, Ahn BC, Yum JS, Chon HJ, Kim C. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. J Immunother Cancer 2022;10:e004799. [PMID: 35764365 DOI: 10.1136/jitc-2022-004799] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Beiss V, Mao C, Fiering SN, Steinmetz NF. Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy. Mol Pharm 2022. [PMID: 35333531 DOI: 10.1021/acs.molpharmaceut.2c00058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mahajan AS, Stegh AH. Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside. Cancers (Basel) 2022;14:1615. [PMID: 35406387 DOI: 10.3390/cancers14071615] [Reference Citation Analysis]
6 Sung JY, Cheong JH. New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment. Cells 2022;11:768. [PMID: 35269390 DOI: 10.3390/cells11050768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Chen X, Zhang Y, Fu Y. The Critical Role of Toll-like Receptor-mediated Signaling in Cancer Immunotherapy. Medicine in Drug Discovery 2022. [DOI: 10.1016/j.medidd.2022.100122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 DePalo DK, Tarhini A, Zager JS. The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. Expert Opin Investig Drugs 2022;:1-10. [PMID: 34996314 DOI: 10.1080/13543784.2022.2027366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li X, Sun X, Guo X, Li X, Peng S, Mu X. Chemical reagents modulate nucleic acid-activated toll-like receptors. Biomed Pharmacother 2022;147:112622. [PMID: 35008000 DOI: 10.1016/j.biopha.2022.112622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kumai T, Yamaki H, Kono M, Hayashi R, Wakisaka R, Komatsuda H. Antitumor Peptide-Based Vaccine in the Limelight. Vaccines (Basel) 2022;10:70. [PMID: 35062731 DOI: 10.3390/vaccines10010070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Karime C, Wang J, Woodhead G, Mody K, Hennemeyer CT, Borad MJ, Mahadevan D, Chandana SR, Babiker H. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34913781 DOI: 10.1080/13543784.2022.2019706] [Reference Citation Analysis]
12 Li Q, Liu Z, Liu Y, Liang C, Shu J, Jin X, Li C, Kou Z. A Combined Adjuvant TF-Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice. Vaccines (Basel) 2021;9:1408. [PMID: 34960154 DOI: 10.3390/vaccines9121408] [Reference Citation Analysis]
13 Leblond MM, Zdimerova H, Desponds E, Verdeil G. Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Cancers (Basel) 2021;13:4712. [PMID: 34572939 DOI: 10.3390/cancers13184712] [Cited by in F6Publishing: 4] [Reference Citation Analysis]